AIM: To investigate the efficacy of a high-potency probiotic preparation on prevention of radiation-induced diarrhea in cancer patients. METHODS: This was a double-blind, placebo-controlled trial. Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) or placebo starting from the first day of radiation therapy. Efficacy endpoints were incidence and severity of radiation-induced diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication. RESULTS: More placebo patients had radiation-induced diarrhea than VSL#3 patients (124 of 239 patients, 51.8%, and 77 of 243 patients, 31.6%; P<0.001) and more patients given placebo suffered grade 3 or 4 diarrhea compared with VSL#3 recipients (55.4% and 1.4%, P<0.001). Daily bowel movements were 14.7 +/- 6 and 5.1 +/- 3 among placebo and VSL#3 recipients (P<0.05), and the mean time to the use of loperamide was 86 +/- 6 h for placebo patients and 122 +/- 8 h for VSL#3 patients (P<0.001). CONCLUSION:Probiotic lactic acid-producing bacteria are an easy, safe, and feasible approach to protect cancer patients against the risk of radiation-induced diarrhea.
RCT Entities:
AIM: To investigate the efficacy of a high-potency probiotic preparation on prevention of radiation-induced diarrhea in cancerpatients. METHODS: This was a double-blind, placebo-controlled trial. Four hundred and ninety patients who underwent adjuvant postoperative radiation therapy after surgery for sigmoid, rectal, or cervical cancer were assigned to either the high-potency probiotic preparation VSL#3 (one sachet t.i.d.,) or placebo starting from the first day of radiation therapy. Efficacy endpoints were incidence and severity of radiation-induced diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication. RESULTS: More placebo patients had radiation-induced diarrhea than VSL#3 patients (124 of 239 patients, 51.8%, and 77 of 243 patients, 31.6%; P<0.001) and more patients given placebo suffered grade 3 or 4 diarrhea compared with VSL#3 recipients (55.4% and 1.4%, P<0.001). Daily bowel movements were 14.7 +/- 6 and 5.1 +/- 3 among placebo and VSL#3 recipients (P<0.05), and the mean time to the use of loperamide was 86 +/- 6 h for placebo patients and 122 +/- 8 h for VSL#3 patients (P<0.001). CONCLUSION: Probiotic lactic acid-producing bacteria are an easy, safe, and feasible approach to protect cancerpatients against the risk of radiation-induced diarrhea.
Authors: Athos Bousvaros; Stefano Guandalini; Robert N Baldassano; Christine Botelho; Jonathan Evans; George D Ferry; Barry Goldin; Lori Hartigan; Subra Kugathasan; Joseph Levy; Karen F Murray; Maria Oliva-Hemker; Joel R Rosh; Vasundhara Tolia; Anna Zholudev; Jon A Vanderhoof; Patricia L Hibberd Journal: Inflamm Bowel Dis Date: 2005-09 Impact factor: 5.325
Authors: Christopher D Jahraus; Doug Bettenhausen; Uzma Malik; Marguerite Sellitti; William H St Clair Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-15 Impact factor: 7.038
Authors: J A Martenson; J W Bollinger; J A Sloan; P J Novotny; R E Urias; J C Michalak; T G Shanahan; J A Mailliard; R Levitt Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: M A Zocco; L Zileri dal Verme; F Cremonini; A C Piscaglia; E C Nista; M Candelli; M Novi; D Rigante; I A Cazzato; V Ojetti; A Armuzzi; G Gasbarrini; A Gasbarrini Journal: Aliment Pharmacol Ther Date: 2006-06-01 Impact factor: 8.171
Authors: M Resbeut; P Marteau; D Cowen; P Richaud; S Bourdin; J B Dubois; P Mere; T D N'Guyen Journal: Radiother Oncol Date: 1997-07 Impact factor: 6.280
Authors: Timothy F Kozelsky; Gregory E Meyers; Jeff A Sloan; Thomas G Shanahan; Stephen J Dick; Randy L Moore; George P Engeler; Albert R Frank; Timothy K McKone; Rodolfo E Urias; Miljenko V Pilepich; Paul J Novotny; James A Martenson Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Matthew A Ciorba; Christopher L Hallemeier; William F Stenson; Parag J Parikh Journal: Curr Opin Support Palliat Care Date: 2015-06 Impact factor: 2.302
Authors: E Kouhsari; A Ghadimi-Daresajini; H Abdollahi; N Amirmozafari; S R Mahdavi; S Abbasian; S H Mousavi; H F Yaseri; M Moghaderi Journal: Clin Transl Oncol Date: 2017-06-16 Impact factor: 3.405